CHILD ARCHIVE CHILD ARCHIVE
0

A setback for immune checkpoint therapy?

Nivolumab, an immunotherapy drug, has shown unprecedented success at treating patients with certain types of advanced cancer. The U.S. Food and Drug Administration approvals for nivolumab, and other drugs like it, are for patients...

CHILD ARCHIVE CHILD ARCHIVE
CHILD ARCHIVE CHILD ARCHIVE
CHILD ARCHIVE CHILD ARCHIVE
CHILD ARCHIVE CHILD ARCHIVE
CHILD ARCHIVE CHILD ARCHIVE
CHILD ARCHIVE

Kite’s CAR T-Cell Therapy Success

Six months after receiving infusions of their own T cells—genetically engineered ex vivo to carry chimeric antigen receptors (CAR) that bind to proteins on the surface of tumor cells—more than one-third of patients with...

CHILD ARCHIVE

The double edge of cancer immunotherapy

Immunotherapies have shown unprecedented efficacy in the treatment of several cancers, including melanoma and lymphoma, and they are now in clinical trials for many others. This type of treatment can differ in form, ranging...

CHILD ARCHIVE CHILD ARCHIVE

Toward Killing Cancer with Bacteria

A genetically manipulated version of the gastroenteritis-causing bacteria Salmonella typhimurium is a potent destroyer of mouse tumors, according to a report published today (February 8) in Science Translational Medicine. The paper adds to a...

CHILD ARCHIVE CHILD ARCHIVE

Locking TNFR2 to kill ovarian cancer

The TNF (tumor necrosis factor) ligand family promotes tumor growth and progression. Torrey et al. developed an antibody that locks TNFR2, a TNF receptor found on immunosuppressive regulatory T cells and some tumor cells,...

CHILD ARCHIVE

Initiating an antitumor attack

Cancer is notorious for relapsing after treatment. Such relapses are driven by tumor-initiating cells, a type of stem cell that gives rise to tumors. Damelin et al. determined that a protein called PTK7 is...

CHILD ARCHIVE
CHILD ARCHIVE CHILD ARCHIVE

Cardiac side effect

Antibodies that block CTLA-4 (cytotoxic T lymphocyte–associated antigen 4) and PD-1 (programmed death 1) allow T cells to launch antitumor immune responses. Although these checkpoint inhibitors improve survival in melanoma patients, inflammation of other...

CHILD ARCHIVE CHILD ARCHIVE
CHILD ARCHIVE